EUVIMEDEUVIMED entdecken
Crossref

Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial

Panot Sainamthip iD, Meenakshi Somadasan iD, Leigh Culnane, Elizabeth Andrews, Lauren Brais iD, Molly Andrews, Gun Ho Jang, Amy Zhang iD, Julie M Wilson iD, Stephanie Ramotar iD, Anna Dodd, Kimberly J Perez iD und 13 weitere

JCO Precision Oncology · 2026-11 · 10 (11)

DOI: 10.1200/po-26-00511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-11. Verfasst von Panot Sainamthip und 24 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Clonal Hematopoiesis. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Clonal hematopoiesis (CH) is increasingly recognized as a proinflammatory driver of adverse outcomes in solid tumors. Tumor-infiltrating immune cells with CH (TI-CH) actively promote tumor growth and those harboring TI-CH experience significantly worse survival. We investigated the prevalence and impact of CH on outcomes in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC).

Methods

Peripheral blood from 125 patients with metastatic PDAC enrolled in the PASS-01 trial (ClinicalTrials.gov identifier: NCT04469556 ) was evaluated. CH was defined as the presence of pathogenic or likely pathogenic variants with a variant allele frequency (VAF) of ≥1% in a 23 gene panel. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazards regression.

Results

CH was detected in 36.8% (46 of 125) of patients, and DNMT3A (60.9%) and TET2 (17.4%) were the most frequently mutated genes. There was no significant difference in progression-free survival (PFS; median, 4.9 v 5.2 months; HR, 1.01 [95% CI, 0.68 to 1.49]; P = .95) and overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively. Among patients with basal-like subtype (n = 23), the presence of CH was associated with a numerically shorter PFS (median, 2.4 v 4.7 months; HR, 2.50 [95% CI, 0.93 to 6.84]; P = .06) and OS (median, 6.2 v 10.2 months; HR, 1.37 [95% CI, 0.51 to 3.69]; P = .52). In contrast, classical subtype showed no significant differences in survival outcomes by CH.

Conclusion

CH is prevalent in metastatic PDAC but not independently prognostic. Further examination of CH in basal subtype tumors and the role of TI-CH in PDAC is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsClonal HematopoiesisHumansFemaleMaleAgedMiddle AgedNeoplasm Metastasis

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA.
  • Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Department of Medicine and David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York City, NY.
  • Johns Hopkins, Baltimore, MD.

ORCID-Profile: Panot Sainamthip, Meenakshi Somadasan, Lauren Brais, Amy Zhang, Julie M Wilson, Stephanie Ramotar, Kimberly J Perez, Kenneth Yu, Daniel Laheru, Daniel A King, Grainne M O'Kane, Steven Gallinger, Elizabeth M Jaffee, Andrew J Aguirre, Brian M Wolpin, Adam S Sperling, Harshabad Singh

Zitieren

APA

Sainamthip, P., Somadasan, M., Culnane, L., Andrews, E., Brais, L., Andrews, M., Jang, G. H., Zhang, A., Wilson, J. M., Ramotar, S., Dodd, A., Perez, K. J., Yu, K., Laheru, D., King, D. A., O'Kane, G. M., Gallinger, S., Tuveson, D., Jaffee, E. M., …, & Singh, H. (2026). Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial. JCO Precision Oncology, 10(11). https://doi.org/10.1200/po-26-00511

Vancouver

Sainamthip P, Somadasan M, Culnane L, Andrews E, Brais L, Andrews M, et al. Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial. JCO Precision Oncology. 2026;10(11). doi:10.1200/po-26-00511

BibTeX
@article{Sainamthip2026,
  author = {Sainamthip, Panot and Somadasan, Meenakshi and Culnane, Leigh and Andrews, Elizabeth and Brais, Lauren and Andrews, Molly and Jang, Gun Ho and Zhang, Amy and Wilson, Julie M and Ramotar, Stephanie and Dodd, Anna and Perez, Kimberly J and Yu, Kenneth and Laheru, Daniel and King, Daniel A and O'Kane, Grainne M and Gallinger, Steven and Tuveson, David and Jaffee, Elizabeth M and Knox, Jennifer J and Notta, Faiyaz and Aguirre, Andrew J and Wolpin, Brian M and Sperling, Adam S and Singh, Harshabad},
  title = {Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {11},
  doi = {10.1200/po-26-00511}
}
Kostenlos starten →